brook house pharma limited Company Information
Company Number
11341417
Website
-Registered Address
8 beehive lane, ilford, IG1 3RD
Industry
Dispensing chemist in specialised stores
Telephone
-
Next Accounts Due
December 2024
Group Structure
View All
Shareholders
ariel oberlander 52%
suzanne oberlander 48%
brook house pharma limited Estimated Valuation
Pomanda estimates the enterprise value of BROOK HOUSE PHARMA LIMITED at £18.8k based on a Turnover of £100.5k and 0.19x industry multiple (adjusted for size and gross margin).
brook house pharma limited Estimated Valuation
Pomanda estimates the enterprise value of BROOK HOUSE PHARMA LIMITED at £39.1k based on an EBITDA of £21.1k and a 1.85x industry multiple (adjusted for size and gross margin).
brook house pharma limited Estimated Valuation
Pomanda estimates the enterprise value of BROOK HOUSE PHARMA LIMITED at £0 based on Net Assets of £-39.8k and 2.03x industry multiple (adjusted for liquidity).
Brook House Pharma Limited AI Business Plan
In just minutes, we combine Pomanda’s company and industry data with cutting edge Artificial Intelligence to build a comprehensive 27 section business plan. You then have 60 days to tailor the information, decide which sections to include or exclude, and add your own branding logos, images and color scheme to create your perfect plan.
Brook House Pharma Limited Overview
Brook House Pharma Limited is a live company located in ilford, IG1 3RD with a Companies House number of 11341417. It operates in the dispensing chemist in specialised stores sector, SIC Code 47730. Founded in May 2018, it's largest shareholder is ariel oberlander with a 52% stake. Brook House Pharma Limited is a young, micro sized company, Pomanda has estimated its turnover at £100.5k with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Brook House Pharma Limited Health Check
Pomanda's financial health check has awarded Brook House Pharma Limited a 2 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 6 areas for improvement. Company Health Check FAQs
1 Strong
3 Regular
6 Weak
Size
annual sales of £100.5k, make it smaller than the average company (£12.1m)
- Brook House Pharma Limited
£12.1m - Industry AVG
Growth
3 year (CAGR) sales growth of -60%, show it is growing at a slower rate (5.2%)
- Brook House Pharma Limited
5.2% - Industry AVG
Production
with a gross margin of 26.3%, this company has a comparable cost of product (31.4%)
- Brook House Pharma Limited
31.4% - Industry AVG
Profitability
an operating margin of 21% make it more profitable than the average company (3.5%)
- Brook House Pharma Limited
3.5% - Industry AVG
Employees
with 1 employees, this is below the industry average (84)
1 - Brook House Pharma Limited
84 - Industry AVG
Pay Structure
on an average salary of £22k, the company has an equivalent pay structure (£22k)
- Brook House Pharma Limited
£22k - Industry AVG
Efficiency
resulting in sales per employee of £100.5k, this is less efficient (£139.2k)
- Brook House Pharma Limited
£139.2k - Industry AVG
Debtor Days
it gets paid by customers after 51 days, this is later than average (30 days)
- Brook House Pharma Limited
30 days - Industry AVG
Creditor Days
its suppliers are paid after 64 days, this is close to average (67 days)
- Brook House Pharma Limited
67 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Brook House Pharma Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Brook House Pharma Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 381.7%, this is a higher level of debt than the average (61%)
381.7% - Brook House Pharma Limited
61% - Industry AVG
brook house pharma limited Credit Report and Business Information
Brook House Pharma Limited Competitor Analysis
Perform a competitor analysis for brook house pharma limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
brook house pharma limited Ownership
BROOK HOUSE PHARMA LIMITED group structure
Brook House Pharma Limited has no subsidiary companies.
Ultimate parent company
BROOK HOUSE PHARMA LIMITED
11341417
brook house pharma limited directors
Brook House Pharma Limited currently has 2 directors. The longest serving directors include Mr Ariel Oberlander (May 2018) and Mrs Suzanne Oberlander (May 2018).
officer | country | age | start | end | role |
---|---|---|---|---|---|
Mr Ariel Oberlander | England | 59 years | May 2018 | - | Director |
Mrs Suzanne Oberlander | England | 62 years | May 2018 | - | Director |
BROOK HOUSE PHARMA LIMITED financials
Brook House Pharma Limited's latest turnover from March 2023 is estimated at £100.5 thousand and the company has net assets of -£39.8 thousand. According to their latest financial statements, Brook House Pharma Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | |
---|---|---|---|---|---|
Turnover | |||||
Other Income Or Grants | |||||
Cost Of Sales | |||||
Gross Profit | |||||
Admin Expenses | |||||
Operating Profit | |||||
Interest Payable | |||||
Interest Receivable | |||||
Pre-Tax Profit | |||||
Tax | |||||
Profit After Tax | |||||
Dividends Paid | |||||
Retained Profit | |||||
Employee Costs | |||||
Number Of Employees | 1 | 2 | 4 | 3 | 4 |
EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | |
---|---|---|---|---|---|
Tangible Assets | 0 | 0 | 405,895 | 430,523 | 455,351 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 |
Investments & Other | 0 | 0 | 0 | 0 | 0 |
Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 |
Total Fixed Assets | 0 | 0 | 405,895 | 430,523 | 455,351 |
Stock & work in progress | 0 | 0 | 0 | 0 | 0 |
Trade Debtors | 14,132 | 112,468 | 458,431 | 471,017 | 464,742 |
Group Debtors | 0 | 0 | 0 | 0 | 0 |
Misc Debtors | 0 | 0 | 0 | 0 | 0 |
Cash | 0 | 0 | 0 | 0 | 0 |
misc current assets | 0 | 0 | 0 | 0 | 0 |
total current assets | 14,132 | 112,468 | 458,431 | 471,017 | 464,742 |
total assets | 14,132 | 112,468 | 864,326 | 901,540 | 920,093 |
Bank overdraft | 0 | 0 | 0 | 0 | 0 |
Bank loan | 0 | 0 | 0 | 0 | 0 |
Trade Creditors | 13,152 | 125,483 | 317,274 | 317,041 | 312,612 |
Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 |
other short term finances | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 |
other current liabilities | 0 | 0 | 0 | 0 | 0 |
total current liabilities | 13,152 | 125,483 | 317,274 | 317,041 | 312,612 |
loans | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 |
Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 |
other liabilities | 40,786 | 43,891 | 613,593 | 645,354 | 660,706 |
provisions | 0 | 0 | 0 | 0 | 0 |
total long term liabilities | 40,786 | 43,891 | 613,593 | 645,354 | 660,706 |
total liabilities | 53,938 | 169,374 | 930,867 | 962,395 | 973,318 |
net assets | -39,806 | -56,906 | -66,541 | -60,855 | -53,225 |
total shareholders funds | -39,806 | -56,906 | -66,541 | -60,855 | -53,225 |
Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | |
---|---|---|---|---|---|
Operating Activities | |||||
Operating Profit | |||||
Depreciation | 0 | 0 | |||
Amortisation | 0 | 0 | |||
Tax | |||||
Stock | 0 | 0 | 0 | 0 | 0 |
Debtors | -98,336 | -345,963 | -12,586 | 6,275 | 464,742 |
Creditors | -112,331 | -191,791 | 233 | 4,429 | 312,612 |
Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 |
Cash flow from operations | |||||
Investing Activities | |||||
capital expenditure | |||||
Change in Investments | 0 | 0 | 0 | 0 | 0 |
cash flow from investments | |||||
Financing Activities | |||||
Bank loans | 0 | 0 | 0 | 0 | 0 |
Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 |
Other Short Term Loans | 0 | 0 | 0 | 0 | 0 |
Long term loans | 0 | 0 | 0 | 0 | 0 |
Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 |
other long term liabilities | -3,105 | -569,702 | -31,761 | -15,352 | 660,706 |
share issue | |||||
interest | |||||
cash flow from financing | |||||
cash and cash equivalents | |||||
cash | 0 | 0 | 0 | 0 | 0 |
overdraft | 0 | 0 | 0 | 0 | 0 |
change in cash | 0 | 0 | 0 | 0 | 0 |
P&L
March 2023turnover
100.5k
-80%
operating profit
21.1k
0%
gross margin
26.3%
-4.37%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2023net assets
-39.8k
-0.3%
total assets
14.1k
-0.87%
cash
0
0%
net assets
Total assets minus all liabilities
Similar Companies
brook house pharma limited company details
company number
11341417
Type
Private limited with Share Capital
industry
47730 - Dispensing chemist in specialised stores
incorporation date
May 2018
age
6
accounts
Micro-Entity Accounts
ultimate parent company
previous names
N/A
incorporated
UK
address
8 beehive lane, ilford, IG1 3RD
last accounts submitted
March 2023
brook house pharma limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 1 charges/mortgages relating to brook house pharma limited. Currently there are 0 open charges and 1 have been satisfied in the past.
brook house pharma limited Companies House Filings - See Documents
date | description | view/download |
---|